Blog, News and Events

We are revolutionizing the translational potential of animal models in preclinical research. Discover the latest articles and news about our recent activities.

Selecting the best model for preclinical hepatitis studies

How can humanized liver models provide accurate efficacy measurements at each stage of the viral lifecycle? Hepatitis B is a serious global health threat. Around 1.5 million hepatitis B virus (HBV) infections were identified in 2019 alone and around 296 million people are thought to be living with the chronic disease.¹ Researchers are now targeting previously unexplored areas of the viral lifecycle to get closer to developing a complete cure.

Topics icon PXB-mouse, News, Blog

How PXB-mice with humanized livers enable better translational outcomes for gene-based therapeutics

In recent years, we have seen an explosion in the number of adeno-associated virus (AAV) vector-based gene therapies progressing to clinical trial stages, and subsequently an increasing number of regulatory successes. The reasons for this are clear. The versatility of AAV-based platforms makes them prime technology for targeting a range of tissues and pathologies, through their ability to silence, replace or modify genes.

Topics icon PXB-mouse, News, Blog

Humanized liver mouse models translation of antivirals for HBV and HDV

Generating high-quality, pre-clinical data is always challenging, but it is especially so when developing therapeutics for hepatitis B and D. Since Hepatitis B Virus (HBV) and Hepatitis D Virus (HDV) only infect human hepatocytes, conventional animal models instantly pose a challenge as the entire viral lifecycle cannot be observed, and the data often doesn’t translate well to the human environment. These issues can lead to misleading metabolism, pharmacokinetics, efficacy and hepatotoxicity data, which can result in wasted time, money and resources and, potentially, failure at clinical trial stages.

Topics icon PXB-mouse, News, Blog

EASL Congress 2023 Meeting

PhoenixBio is delighted to be attending the EASL Congress in person at the Messe Wien Exhibition Congress Center in Vienna, Austria on June 21st - 24th, 2023. We'll be exhibiting our products & services at booth #E14. Meet with our team to learn more about PhoenixBio's capabilities and how we can help you advance and deliver tomorrow’s therapies.

Topics icon Events

American Association for the Study of Liver Diseases 2022 Meeting

PhoenixBio is delighted to be attending AASLD in person at the Walter E. Washington Convention Center in Washington, DC on November 4th - 8th, 2022. We'll be exhibiting our products & services at booth #714. Meet with our team to learn more about PhoenixBio's capabilities and how we can help you advance and deliver tomorrow’s therapies.

Topics icon Events

AASLD 2022

Attending the International HBV Meeting 2022

PhoenixBio is thrilled to be attending the International HBV Meeting in person at the Novotel Paris Centre Tour Eiffel in Paris, France on September 18th - 22nd, 2022. Meet with our team to learn more about PhoenixBio's capabilities and how we can help you advance future therapies for viral hepatitis (HBV, HDV/HBV, HCV), Gene Editing, Gene Therapy, Drug Metabolism, Pharmacokinetics, and Toxicology.

Topics icon Exhibition, Events

HBV Meeting

Attending EASL's International Liver Congress

PhoenixBio is thrilled to be attending EASL's International Liver Congress in person at the ExCeL in London, UK on June 22nd - 26th, 2022. Meet with our team to learn more about PhoenixBio's capabilities and how we can help you advance future therapies for HBV, HDV/HBV, HCV, NASH/NAFLD, Gene Editing, Gene Therapy, Drug Metabolism, Pharmacokinetics, and Toxicology.

Topics icon Events

EASL International Liver Congress 2022 in London

Sign-up to our newsletter for the latest news and information straight to your inbox